CANbridge Pharmaceuticals Inc.
HHKEX:1228Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Qun Xue
- Full Time Employees
- 41
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Suzhou Industrial Park, Building 21 Beijing BE China
- IPO Date
- Dec 10, 2021
- Website
- canbridgepharma.com
- Similar Companies
- Business
- CANbridge Pharmaceuticals Inc. (HKEX:1228) is a global biopharmaceutical company focused on the research, development and commercialization of transformative therapies for rare diseases, with a foundation in China. Established in 2012 and headquartered in Suzhou, China, the company offers approved products including Hunterase (idursulfase beta), an enzyme replacement therapy for Mucopolysaccharidosis type II (Hunter syndrome); Livmarli (maralixibat oral solution), an ileal bile acid transporter inhibitor for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis; and Gaurunning (velaglucerase beta for injection), an enzyme replacement therapy for Type 1 and Type 3 Gaucher disease. Its pipeline comprises seven assets such as CAN106 (omoprubart), a long-acting monoclonal antibody for complement-mediated disorders including paroxysmal nocturnal hemoglobinuria; gene therapies for Pompe disease, Fabry disease and Duchenne muscular dystrophy developed at its Next-Generation Innovation Facility; and treatments targeting hemophilia A, metabolic disorders and neuromuscular diseases. CANbridge operates across mainland China, Hong Kong, Macau, Taiwan, the United States and collaborates globally with partners including Apogenix, GC Pharma, Mirum Pharmaceuticals, WuXi Biologics, Privus, UMass Chan Medical School, University of Washington School of Medicine and Scriptr Global. In August 2025, CANbridge entered a strategic partnership with Qingdao Baheal Medical Inc., securing approximately HK$100 million in equity investment and designating a Baheal subsidiary as exclusive commercial services organization for select products in mainland China, Hong Kong and Macau to enhance commercialization capabilities; the company also received NMPA marketing approval for Gaurunning in May 2025 via priority review, accepted NDAs for expanded Livmarli indications and advanced CAN106 and gene therapy programs with positive clinical data.
Company News
CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee
CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
CANbridge Announces Marketing Approval of CAN108 (迈芮倍®/LIVMARLI®) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
CANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy Research
CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment
Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database